ArticleTransactions of the American Ophthalmological Society2005
Quality of life in patients with Graves ophthalmopathy.
Article in Transactions of the American Ophthalmological Society, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02316691 (B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease), which is not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.BMJ open ophthalmology · 2024Pooled it
- Thyroid disease-specific quality of life questionnaires - A systematic review.Endocrinology, diabetes & metabolism · 2022Pooled it
- Quality of life in patients with Graves' orbitopathy submitted to orbital decompression: comparison between balanced and inferomedial techniques.Arquivos brasileiros de oftalmologia · 2024Trial
- Impacts of Thyroid Eye Disease (TED), Beyond the Signs and Symptoms: Results from the ElevaTED Patient Survey.Ophthalmology and therapy · 2026Article
- Graves' orbitopathy following Alemtuzumab treatment for multiple sclerosis: a systematic review and real-world insights.Thyroid research · 2025Review
- Epidemiology of orbital diseases in a tertiary ophthalmic outpatient clinic in Sao Paulo, Brazil.Arquivos brasileiros de oftalmologia · 2025Article
- The Potential of Artemisinins as Novel Treatment for Thyroid Eye Disease by Inhibiting Adipogenesis in Orbital Fibroblasts.Investigative ophthalmology & visual science · 2023Article
- Patient needs and care: moves toward person-centered care for Graves' disease in Sweden.European thyroid journal · 2023Review
- Postoperative residual vertical deviation affects quality of life in Asian patients with thyroid-associated ophthalmopathy (Graves ophthalmopathy).Japanese journal of ophthalmology · 2023Article
- Incidence of A pattern strabismus after inferior rectus recession in patients with Graves' orbitopathy: A retrospective multicentre study.Acta ophthalmologica · 2023Article
- Treatment Results of Endoscopic Transnasal Orbital Decompression for Graves' Orbitopathy-A Single-Center Retrospective Analysis in 28 Orbits of 16 Patients.Journal of personalized medicine · 2022Article
- Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society · 2022Article
- Measuring Health-Related Quality of Life in Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2022Article
- Ocular surface disease in thyroid eye disease: A narrative review.The ocular surface · 2022Review
- Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.Ophthalmology and therapy · 2021Article
- Disrupted Spontaneous Neural Activity in Patients With Thyroid-Associated Ophthalmopathy: A Resting-State fMRI Study Using Amplitude of Low-Frequency Fluctuation.Frontiers in human neuroscience · 2021Article
- Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy.European thyroid journal · 2020Article
- Trends in Treatment of Active, Moderate-to-Severe Thyroid Eye Disease in the United States.Journal of the Endocrine Society · 2020Article
- Morphological and microstructural brain changes in thyroid-associated ophthalmopathy: a combined voxel-based morphometry and diffusion tensor imaging study.Journal of endocrinological investigation · 2020Article
- Novel Roles of Chloroquine and Hydroxychloroquine in Graves' Orbitopathy Therapy by Targeting Orbital Fibroblasts.The Journal of clinical endocrinology and metabolism · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the quality of life in patients with Graves ophthalmopathy by means of a prospective questionnaire with validation.
methodsA questionnaire containing 105 items was sent to 325 patients seen in our university-based oculoplastic clinic. Two hundred three questionnaires were returned and were suitable for analysis. Fifty-three consecutive patients with Graves disease who presented to the clinic for examination also completed the questionnaire. The questionnaire was validated by administering it to 33 healthy subjects who had no history of Graves disease or thyroid disorder. The results were compared with those of normal subjects and with national norms for visually impaired populations. The relationship of individual questionnaire items to measures of clinical severity was subsequently assessed.
resultsPatients with Graves ophthalmopathy report greater impairment in both physical (44.4 versus 51.9; P < .001) and mental (43.8 versus 51.8; P < .001) health; poorer self- image (P < .001); and significantly more disturbance in their sleep, social function, and work function (P < .001) than controls. Afflicted patients also experience significantly more diplopia, blurred vision, and dry eye symptoms than controls (P < .001). Individual questionnaire items were found to correlate with clinical disease severity scores and were used to establish a Graves ophthalmopathy quality-of-life questionnaire with disease severity validation.
conclusionsPatients with Graves disease are significantly impaired in their social and vocational function because of the ophthalmic manifestations of the disease. A short questionnaire that correlates with clinical measures of disease severity may be a useful measure of quality of life in this disease.
Indexed as
Identifiers
17057811PMC1447582What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.